Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.

Authors : Farhat F, Tarabaih M, Kanj A, Aoun M, Kattan J, Assi T, Awada A
Year : 2020
Journal : Anticancer Drugs
Volume : 31
Pages : 85-89

Targeted therapy for breast cancer in older patients.

Authors : Pondé N, Wildiers H, Awada A, de Azambuja E, Deliens C, Dal Lago L
Year : 2020
Journal : J Geriatr Oncol
Volume : 11
Pages : 380-388

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study.

Authors : Haltout J, Awada A, Paesmans M, Moreau M, Klastersky J, Machiels G, Ignatiadis M, Kotecki N
Year : 2019
Journal : Support Care Cancer
Volume : 27
Pages : 1163-1170

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

Authors : Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, OShaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 397-404

Personalized Medicine, Genomic Profiling and Germline Mutations: Toward More Precise Decisions.

Authors : Awada A, El Saghir NS
Year : 2019
Journal : J Oncol Pract
Volume : 15
Pages : e755-e757

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.

Authors : Jones RL, Ratain MJ, ODwyer PJ, Siu LL, Jassem J, Medioni J, DeJonge M, Rudin C, Sawyer M, Khayat D, Awada A, de Vos-Geelen JMPGM, Evans TRJ, Obel J, Brockstein B, DeGreve J, Baurain JF, Maki R, DAdamo D, Dickson M, Undevia S, Geary D, Janisch L, Bedard PL, Abdul Razak AR, Kristeleit R, Vitfell-Rasmussen J, Walters I, Kaye SB, Schwartz G
Year : 2019
Journal : Eur J Cancer
Volume : 120
Pages : 132-139

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.

Authors : Krayem M, Sabbah M, Najem A, Wouters A, Lardon F, Simon S, Sales F, Journe F, Awada A, Ghanem G, Van Gestel D
Year : 2019
Journal : Cancers (Basel)
Volume : 11

How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?

Authors : Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A
Year : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 420-423

Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors: lessons learnt and perspectives.

Authors : Kotecki N, Awada A
Year : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 439-444

Therapeutic management of malignant paragangliomas: an illustrative case and literature review.

Authors : Afani L, Errihani H, Awada A
Year : 2019
Journal : Pan Afr Med J
Volume : 32
Pages : 62

Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer.

Authors : Gombos A, Franzoi MA, Awada A
Year : 2019
Journal : Expert Opin Investig Drugs
Volume : 28
Pages : 617-627

The role of direct oral anticoagulants in the management of cancerassociated thrombosis.

Authors : Awada A, Baurain JF, Clement P, Hainaut P, Holbrechts S, Jochmans K, Mathieu V, Mebis J, Strijbos M, Vulsteke C, Vanassche T, Verhamme P
Year : 2019
Journal : Belgian J Hematology
Volume : 10(4)
Pages : 169-176

CANCER DU SEIN AVEC MÉTASTASE INHABITUELLE AU NIVEAU VÉSICAL : RAPPORT DE CAS ET REVUE SYSTÉMATIQUE DE LA LITTÉRATURE

Authors : Marcoux D, Ignatiadis M, Paesmans M, Awada A
Year : 2019
Journal : Rev Med Brux
Volume : 40(3)
Pages : 148-159

Triple negative breast cancer: current treatment and future perspectives.

Authors : El Hachem G, Jounblat Y, Awada A, Gombos A
Year : 2019
Journal : Belgian J Medical Oncology
Volume : 13(3)
Pages : 84-92

The role of direct oral anticoagulants in the management of cancer-associated thrombosis?

Authors : Awada A, Baurain JF, Clement P, Hainaut P, Holbrechts S, Jochmans K, Mathieu V, Mebis J, Strijbos M, Vulsteke C, Vanassche T, Verhamme P
Year : 2019
Journal : Belgian J Medical Oncology
Volume : 13(3)
Pages : 84-92

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

Authors : Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP
Year : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 5

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an <i>ESMO Open-Cancer Horizons</i> pro and con discussion.

Authors : Awada A, Gligorov J, Jerusalem G, Preusser M, Singer C, Zielinski C
Year : 2019
Journal : ESMO Open
Volume : 4
Pages : e000565

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.

Authors : Diéras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, Gligorov J, Jager A, Zambelli S, Lindeman GJ, Charpentier E, Emmons GT, Garcia-Ribas I, Paridaens R, Verweij J
Year : 2019
Journal : Breast Cancer Res Treat
Volume : 177
Pages : 383-393

Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies.

Authors : El Ali Z, Rottey S, Barthelemy P, Kotecki N, VAN Paemel R, Devrient D, Awada A, Gil T, Pannier D, Ryckewaert T, Waisse W, Clavier JB, Penel N, Vermassen T
Year : 2019
Journal : Anticancer Res
Volume : 39
Pages : 2993-3002

Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.

Authors : Kotecki N, Gombos A, Awada A
Year : 2019
Journal : Expert Rev Anticancer Ther
Volume : 19
Pages : 447-454